ECB Gets Another ‘Moderate Hawk' as Dutch Central-Bank Veteran Exits
The 54-year-old economist takes over as the head of the central bank of the Netherlands on Tuesday, succeeding the hawkish Klaas Knot, who was among the most keenly tracked policymakers, despite him hailing from outside the region's top economies.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Brace for Jerome Powell's Jackson Hole speech to drive big swings in this corner of the stock market, BofA says
Markets are bracing for Jerome Powell's speech at Jackson Hole on Friday. Nervousness ahead of the Fed chair's remarks helped spark a sell-off in some high-flying growth shares this week. BofA says that Powell's comments will result in a big impact for small-cap stocks. A sell-off in high-flying growth stocks this week hints at nervousness ahead of Jerome Powell's remarks at Jackson Hole, but there's another area of the stock market where investors should be prepared to see outsize swings after the Fed chief speaks on Friday. Analysts at Bank of America wrote this week that small-caps are likely to see big moves in either direction on the back of Powell's comments on the path of monetary policy during the Fed's annual policy symposium. In an August 20 note, analyst Jill Carey Hall wrote that the speech could prove to be a significant near-term catalyst for the Russell 2000, the index of small-mid cap companies, depending on what it reveals. "A dovish speech could spur a rally, while a more hawkish one could spur near-term downside given market pricing for two cuts by year-end," she said. Powell's speech is expected to set the tone for monetary policy for the rest of the year. A dovish nod toward rate cuts in September and beyond is expected to be a bullish driver for stocks, but there's some doubt over how accommodating the Fed chief will be after the latest round of economic data was a mixed bag. The CME FedWatch Tool shows 73% odds of a rate cut in September, down from nearly 100% a week ago. The analyst added that stocks in the small-cap category have historically outperformed larger peers during rate-cutting cycles that played out close to periods of economic recession. However, in non-recessionary times, their performance has been more mixed. Other investing experts have expressed similar optimism for small- and mid-cap stocks amid the Russell 2000's outperformance over the S&P 500 in the last month. However, the question of whether the US economy is headed toward a recession is presently unclear. "Despite the recent weak employment report, we continue to expect the US economy to avoid recession in 2025," Ben Herzon, economics director at S&P Global Market Intelligence, recently said. Moody's economist Mark Zandi recently said that the US is not in a recession yet, though he sees it as a strong possibility. As such, uncertainty remains high as the market prepares for Powell's address, especially since views are divided over whether he will signal a shift toward a more dovish policy stance. What is clear is that small-cap companies have a lot riding on his speech. As Carey Hall added, "A cut in the absence of weaker macro data could be more positive than historically, given the increased sensitivity of small caps to interest rates/elevated refinancing risk." Read the original article on Business Insider Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Fox News
28 minutes ago
- Fox News
Russia strikes US electronics plant in latest attack on Ukraine
Fox News reporter Stephanie Bennett reports on a new airstrike by Russia that impacted a U.S. electronics plant near the Hungary border on 'Special Report.'
Yahoo
an hour ago
- Yahoo
Oculis Holding AG (OCS) Reports Q2 Loss, Beats Revenue Estimates
Oculis Holding AG (OCS) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to a loss of $0.56 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -11.32%. A quarter ago, it was expected that this company would post a loss of $0.51 per share when it actually produced a loss of $0.77, delivering a surprise of -50.98%. Over the last four quarters, the company has not been able to surpass consensus EPS estimates. Oculis Holding AG, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.32 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 28.54%. This compares to year-ago revenues of $0.27 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Oculis Holding AG shares have added about 3.2% since the beginning of the year versus the S&P 500's gain of 8.7%. What's Next for Oculis Holding AG? While Oculis Holding AG has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Oculis Holding AG was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.54 on $0.25 million in revenues for the coming quarter and -$2.44 on $0.82 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 42% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Phibro Animal Health (PAHC), another stock in the broader Zacks Medical sector, has yet to report results for the quarter ended June 2025. The results are expected to be released on August 27. This maker of animal health products and nutritional supplements is expected to post quarterly earnings of $0.52 per share in its upcoming report, which represents a year-over-year change of +26.8%. The consensus EPS estimate for the quarter has been revised 1% higher over the last 30 days to the current level. Phibro Animal Health's revenues are expected to be $361.15 million, up 32.2% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Oculis Holding AG (OCS) : Free Stock Analysis Report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
